Prostate Cancer Clinical Trials in Baltimore, Maryland

20 studies are recruiting for prostate cancer in Baltimore, Maryland right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

    This is a proof-of-concept study designed to investigate HER3-DXd monotherapy in locally advanced unresectable or metastatic solid tumors. The study is enrolling cohorts of participants with melanoma [cutaneous/acral], squamous cell carcinomas of the head and neck (SCCHN), HER2-negative gastric can…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Johns Hopkins University, Baltimore, Maryland
    Locations
    90 in total
    Run by
    Daiichi Sankyo

    See if you can join NCT06172478 on ClinicalTrials.gov

  2. A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

    Researchers are looking for new ways to treat metastatic castration-resistant prostate cancer (mCRPC). Researchers have designed a study medicine called ifinatamab deruxtecan (also called I-DXd or MK-2400) to treat mCRPC. The goal of this study is to learn if people who receive I-DXd live longer ov…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Greenebaum Comprehensive Cancer Center ( Site 0021), Baltimore, Maryland
    Locations
    298 in total
    Run by
    Merck Sharp & Dohme LLC

    See if you can join NCT06925737 on ClinicalTrials.gov

  3. PROMISE Registry: A Prostate Cancer Registry of Outcomes and Germline Mutations for Improved Survival and Treatment Effectiveness

    PROMISE aims to create a comprehensive nationwide registry of prostate cancer patients with germline pathogenic variants by prospectively screening approximately 5,000 subjects with a confirmed prostate cancer diagnosis, either through tissue biopsy, PSA greater than 100 ng/dL and/or radiographic e…

    Stage
    Not phased
    Ages
    18 and older
    Site
    Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland
    Locations
    3 in total
    Run by
    Prostate Cancer Clinical Trials Consortium

    See if you can join NCT04995198 on ClinicalTrials.gov

  4. Patient Navigation Program to Improve Clinical Trial Enrollment in Cancer Patients

    The goal of this clinical trial is to test the utility of patient navigation by comparing high intensity patient navigation to low intensity navigation approaches to improving cancer trial enrollment of patients treated in academic and community cancer centers. Patient navigation is a strategy for …

    Stage
    Not phased
    Ages
    18 and older
    Site
    Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland
    Locations
    2 in total
    Run by
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

    See if you can join NCT06138067 on ClinicalTrials.gov

  5. Transrectal Ultrasound Robot-Assisted Prostate Biopsy

    Prostate cancer (PCa) is the most common non-dermatologic malignancy in U.S. men. Transrectal ultrasound (TRUS)-guided prostate biopsy is a commonly used diagnostic procedure for men with an elevated serum prostate-specific antigen (PSA) level and/or abnormal digital rectal examination (DRE). It is…

    Stage
    Not phased
    Ages
    45 to 75
    Site
    Johns Hopkins Hospital, Baltimore, Maryland
    Run by
    Johns Hopkins University

    See if you can join NCT02871726 on ClinicalTrials.gov

  6. Study of Oral MRT-2359 With Apalutamide in Prostate Cancer

    This Phase 2, open-label, multicenter study is conducted in patients with castration-resistant prostate cancer. Patients in this study receive MRT-2359, an investigational oral medicine, in combination with apalutamide, an oral medicine used to treat prostate cancer. The main purpose of the study i…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    University of Maryland Greenebaum Cancer Center, Baltimore, Maryland
    Locations
    14 in total
    Run by
    Monte Rosa Therapeutics, Inc

    See if you can join NCT07745361 on ClinicalTrials.gov

  7. A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC

    This is a dose-finding study to assess the safety and preliminary antitumor activity of Pocenbrodib alone or with darolutamide in patients with metastatic castration-resistant prostate cancer (mCRPC)

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Johns Hopkins Hospital, Baltimore, Maryland
    Locations
    19 in total
    Run by
    Pathos AI, Inc.

    See if you can join NCT06785636 on ClinicalTrials.gov

  8. FOG-001 in Locally Advanced or Metastatic Solid Tumors

    The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors or in participants with familial adenomatous polyposis (FAP).

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Johns Hopkins University, The Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland
    Locations
    33 in total
    Run by
    Parabilis Medicines, Inc.

    See if you can join NCT05919264 on ClinicalTrials.gov

  9. Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)

    This study is a first-in-human, Phase 1, open-label, multicenter study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and the preliminary efficacy of JANX007 in adults with metastatic castration-resistant prostate cancer (mCRPC).

    Stage
    Phase 1
    Ages
    18 to 100
    Site
    University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, Maryland
    Locations
    36 in total
    Run by
    Janux Therapeutics

    See if you can join NCT05519449 on ClinicalTrials.gov

  10. 7-Days Water-Only Fasting or Ketone Supplementation Trial in Prostate Cancer

    Activating the immune system to kill cancer cells is a promising therapeutic strategy for some patients with cancer. Unfortunately, current immune-targeting treatments do not work for patients with prostate cancer. In animal models of cancer, fasting can reprogram the body's metabolism and immune c…

    Stage
    Not phased
    Ages
    18 and older
    Site
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland
    Run by
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

    See if you can join NCT06826924 on ClinicalTrials.gov

  11. TERPS Trial for de Novo Oligometastic Prostate Cancer

    This research is being done to see if we can improve the outcome of prostate cancer patients who present with metastatic lesions at initial diagnosis.

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Maryland Proton Treatment Center, Baltimore, Maryland
    Locations
    10 in total
    Run by
    University of Maryland, Baltimore

    See if you can join NCT05223803 on ClinicalTrials.gov

  12. International Registry for Men With Advanced Prostate Cancer (IRONMAN)

    Our intent is to establish the International Registry to Improve Outcomes in Men with Advanced Prostate Cancer (IRONMAN) as a prospective, international cohort of minimum 5,000 men with advanced cancer, including men with mHSPC and M0/M1 CRPC. The goal is to establish a population-based registry an…

    Stage
    Not phased
    Ages
    21 and older
    Site
    Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland
    Locations
    121 in total
    Run by
    Prostate Cancer Clinical Trials Consortium

    See if you can join NCT03151629 on ClinicalTrials.gov

  13. Clinical Trial of Approaches to Prostate Cancer Surgery

    This is a prospective, randomized controlled trial to compare cancer control and health-related quality of life following pelvic fascia-sparing radical prostatectomy versus standard radical prostatectomy. The investigators hypothesize that pelvic fascia-sparing radical prostatectomy will have simil…

    Stage
    Not phased
    Ages
    40 to 80
    Site
    Johns Hopkins University, Baltimore, Maryland
    Locations
    9 in total
    Run by
    Weill Medical College of Cornell University

    See if you can join NCT05155501 on ClinicalTrials.gov

  14. Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer

    This is a prospective, open-label, multi-center seamless phase II to phase III randomized clinical trial designed to compare SST with or without PET-directed local therapy in improving the castration-resistant prostate cancer-free survival (CRPC-free survival) for Veterans with oligometastatic pros…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Baltimore VA Medical Center VA Maryland Health Care System, Baltimore, MD, Baltimore, Maryland
    Locations
    20 in total
    Run by
    VA Office of Research and Development

    See if you can join NCT04787744 on ClinicalTrials.gov

  15. SPECT Imaging for Pharmacokinetics and dosimEtry Towards TREATment Optimization

    The investigators will study SPECT imaging of radiopharmaceutical therapies given as standard of care or as part of other compatible research protocols. The goal is to validate the quantitative SPECT image reconstruction methods developed in this proposal, and to investigate the relation between do…

    Stage
    Not phased
    Ages
    18 to 100
    Site
    Johns Hopkins University, Baltimore, Maryland
    Run by
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

    See if you can join NCT06389097 on ClinicalTrials.gov

  16. Image-guided Focal Brachytherapy Utilizing Combined 18F-DCFPyl PET/CT

    The Principal Investigator's (PI) working hypothesis is that the PI can utilize the high predictive value of 18F-DCFPyl PSMA to identify clinically significant tumors in patients who will undergo brachytherapy, as well as areas which are uninvolved or contain only clinically insignificant disease. …

    Stage
    EARLY_Phase 1
    Ages
    18 to 100
    Site
    SKCCC at Johns Hopkins, Baltimore, Maryland
    Run by
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

    See if you can join NCT03861676 on ClinicalTrials.gov

  17. A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

    Phase 1 dose escalation and expansion study of CLSP-1025, a first-in-class HLA-A*02:01 specific T cell engager (TCE) targeting solid tumors that harbor the p53 R175H mutation.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Johns Hopkins - Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland
    Locations
    21 in total
    Run by
    Clasp Therapeutics, Inc.

    See if you can join NCT06778863 on ClinicalTrials.gov

  18. Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer

    Asymptomatic patients with metastatic castrate resistant prostate cancer (mCRPC) without pain due to prostate cancer will be treated on an open label study to evaluate effectiveness of sequential treatment with the combination of difluoromethylornithine (DFMO) and high dose testosterone in sequence…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Johns Hopkins University: Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland
    Run by
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

    See if you can join NCT06059118 on ClinicalTrials.gov

  19. Exercise in Prostate Cancer

    The goal of this clinical trial is to learn how exercise intervention affects circulating tumor cells (CTC) in men with advanced prostate cancer. The primary objective is to determine if an exercise intervention decreases CTCs in men with advanced prostate cancer. Participants will have baseline sc…

    Stage
    Not phased
    Ages
    18 to 80
    Site
    Johns Hopkins University, Baltimore, Maryland
    Run by
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

    See if you can join NCT06165302 on ClinicalTrials.gov

  20. A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies

    ATLAS-101 is a Phase I/II clinical trial of AMXI-5001 in adult participants with advanced malignancies who have previously failed other therapies. The study has two phases. The purpose of Phase I (Dose Escalation) is to confirm the appropriate treatment dose and Phase II (Dose Expansion) is to char…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Johns Hopkins, Baltimore, Maryland
    Locations
    4 in total
    Run by
    AtlasMedx, Incorporated

    See if you can join NCT04503265 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.